NCT06878976Phase 3Enrolling by invitation

A Study to Assess the Long-term Safety and Efficacy of Solriamfetol in Subjects With Binge Eating Disorder

Study sponsor: Axsome Therapeutics, Inc. · AXSM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-12Estimated
Enrollment · participants236Estimated
Source updated2026-11-06Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Long-term Safety. After: Measure: Time from randomization to relapse of binge eating in the RW segment.

Planned enrollment decreased by 64 participants

Before: 300 participants (planned). After: 236 participants (planned).

Primary completion date changed

Before: Dec 2026. After: Dec 2027.

Check registry source